FDA accepts Merck's grass pollen allergy treatment for review

03/29/2013 | Pharmaceutical Business Review Online · USA Today

Merck said the FDA has accepted its biologics-license application for an experimental immunotherapy to treat grass pollen allergy. Instead of providing temporary relief of allergy symptoms, the treatment targets the causes of the allergic reaction and reduces symptoms such as itching and sneezing gradually. Merck expects the agency to release its decision early next year.

View Full Article in:

Pharmaceutical Business Review Online · USA Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD